Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 Years and older
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:completedIn |
June 2022
|
| gptkbp:condition |
gptkb:COVID-19
|
| gptkbp:enrollment |
1200
|
| gptkbp:gender |
All
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT03888612
|
| gptkbp:intervention |
gptkb:PF-07321332
gptkb:Ritonavir Parallel Assignment |
| gptkbp:location |
gptkb:Argentina
gptkb:Brazil gptkb:Germany gptkb:Japan gptkb:South_Africa gptkb:United_States |
| gptkbp:mask |
Double
|
| gptkbp:officialName |
A Study of PF-07321332/Ritonavir in Nonhospitalized High-Risk Adult Participants With COVID-19
|
| gptkbp:purpose |
Treatment
|
| gptkbp:recognizedBy |
gptkb:NCT03888612
|
| gptkbp:result |
Proportion of participants with COVID-19 related hospitalization or death from any cause through Day 28
|
| gptkbp:sponsor |
gptkb:Pfizer
|
| gptkbp:startDate |
April 2019
|
| gptkbp:status |
Completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:Targeted_Protein_Degradation
|
| gptkbp:bfsLayer |
8
|